Use access key #2 to skip to page content.
$11.63 0.00 (0.00%)
9/30/2008 4:00 PM

AVANT Immunotherapeutics, Inc. (AVAN)

CAPS Rating:
***

A biopharmaceutical company engaged in the discovery, development and commercialization of products that harness the human immune response to prevent and treat disease.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating AVAN

Add Stock to Watchlist

What the Community Thinks

Total Members

90 Outperforms
7 Underperforms
 

All-Stars

15 Outperforms
3 Underperforms
 

Wall Street

2 Outperforms
0 Underperforms
 

Members bullish on AVAN are also bullish on:

Members bearish on AVAN are also bearish on:

Ticker Tags

Micro Cap (4824), Biotechnology (295), Diagnostic Substances (53)
Suggest a tag

AVANT Immunotherapeutics, Inc. At A Glance

Current Price: $11.63
Last Trade Time: 9/30/2008 4:00 PM
Open: $0.00
Previous Close: $11.63
Daily Range: $10.89 - $11.68
52-Week Range: $9.67 - $19.79
Volume: 56,588
Market Cap: $182.68M
P/E Ratio: 0.00
Compare Our Special Broker Offers!

Stock Trends

AVAN VS S&P 500 (SPY)

AVAN 12 month chart vs. S&P

News & Discussion Boards

Top Bull Pitch

Recs

1

AVANT Immunotherapeutics, Inc. (AVAN)

Avatar Godstrigger (96.35) Submitted: 4/08/08 1:37 AM

The rotavirus vaccine will be incorporated into every childs immunization schedule. The Baby medicine market is recession proof! The research and development secto of this company will have a wide impact on our health in the future And quite possibly be influential in developing vaccines for the d...More

Replies: 0 | Reply | Permalink

Top Bear Pitch

Recs

1

AVANT Immunotherapeutics, Inc. (AVAN)

Avatar denkab (51.51) Submitted: 6/02/08 2:32 PM

I'm just bitter someone may have reaped profit in excess of 1500%

Replies: 0 | Reply | Permalink

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 15 :   1 2 3 Next »

Recs

0

 (AVAN)

Avatar Actionman2go (< 20) Submitted: 9/24/08 8:47 AM : Outperform Start Price: $11.99 AVAN Score: 13.04

Promising brain cancer drug manufacturer. Has gone up 744 percent since I started following it two years ago at a $1.42 stock price.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (AVAN)

Avatar nikkobear (21.77) Submitted: 6/18/08 10:21 PM : Outperform Start Price: $14.36 AVAN Score: 6.41

had a nice pop, but has dropped 5 dollars a share in less than a month, this one will take time to prove itself

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (AVAN)

Avatar icetogo (< 20) Submitted: 6/14/08 9:04 AM : Outperform Start Price: $16.32 AVAN Score: -2.13

Researchand development is going to pay dividends, as well as it's asscociation with Pfizer.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (AVAN)

Avatar ChannelDunlap (< 20) Submitted: 6/07/08 12:57 PM : Outperform Start Price: $17.51 AVAN Score: -6.56

Just trying to get in before the next 500% jump :)

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (AVAN)

Avatar chtrplyr (58.44) Submitted: 6/06/08 3:29 PM : Underperform Start Price: $17.35 AVAN Score: 5.94

It will be bought out at $5 when it runs out of money which is has none of now along with huge losses.

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 15 :   1 2 3 Next »

Wall Street

Results 1 - 2 of 2  

picks per page. CHANGE Expand All Pitches

Top
Pick
Member NameMember RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackNeedham < 20 04/17/08 Outperform NS $12.37-5.98%-26.76%+20.78
TrackEveillard 84.91 09/30/07 Outperform NS $6.72+73.07%-34.44%+107.51 Toggle the visibility of 60-Second Pitch and replies

Results 1 - 2 of 2  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners